Real-world patterns of romiplostim treatment in adults with primary immune thrombocytopenia in the United States

Real-world patterns of romiplostim treatment in adults with ITP—including treatment duration, dose modifications, and discontinuation—had not been characterized in a large US hematology practice dataset.

Target RWE researchers analyzed real-world hematology data to describe romiplostim treatment patterns in adult ITP patients, characterizing dose trajectories, treatment duration, and rates of discontinuation or switching.

Providing an early characterization of real-world romiplostim treatment patterns informs Amgen's commercial strategy and contributes to the evidence base for optimal romiplostim use.

Romiplostim real-world treatment pattern characterization for ITP clinical practice and Amgen commercial strategy, Dose trajectory and discontinuation evidence for romiplostim prescriber education in ITP management